IDev Technologies
Founded Year
2006Stage
Acquired | AcquiredTotal Raised
$107.87MValuation
$0000About IDev Technologies
IDev Technologies is a medical device company engaged in the development and commercialization of a woven nitinol wire, self expanding stent for treatment of peripheral arterial stenosis. IDEV Technologies' products include SUPERA Veritas, a self-expanding nitinol stent system with CE Mark in Europe for treating blockages in blood vessels due to peripheral artery disease (PAD). Stents are used to prop open a blocked vessel and prevent re-blockage. With its proprietary interwoven wire technology, SUPERA Veritas is designed based on biomimetic principles – attempting to mimic the body's natural movement – to promote blood flow in the treated area while offering strength and flexibility. These properties are particularly important when considering treatment for blockages in the blood vessels in the thigh and knee where rapid and frequent movement occurs with daily activities such as walking, sitting and standing. In August 2013, IDev Technologies was acquired by Abbott Laboratories. The valuation of IDev Technologies was $310 million. Other terms of the deal were not released.
Missing: IDev Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: IDev Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
IDev Technologies Patents
IDev Technologies has filed 24 patents.
The 3 most popular patent topics include:
- Implants (medicine)
- Gastropod anatomy
- Transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/27/2021 | 6/14/2022 | Welding, Implants (medicine), Gastropod anatomy, Transcription factors, Niobium minerals | Grant |
Application Date | 5/27/2021 |
|---|---|
Grant Date | 6/14/2022 |
Title | |
Related Topics | Welding, Implants (medicine), Gastropod anatomy, Transcription factors, Niobium minerals |
Status | Grant |
Latest IDev Technologies News
Sep 23, 2014
Tweet September 23, 2014 by Alexander Soule Abbott Vascular plans to shutter a plant in Texas that makes its Supera peripheral stents as it shifts production and 50 jobs to another plant in California. Abbott (NYSE: ABT ) said it plans to shutter the Webster, Texas plant it acquired along with IDEV Technologies last year and move production and 50 jobs to another site in California. Abbott Vascular, which is in the middle of a restructuring plan aimed at streamlining operations and improvinge earnings, revealed the closing of the Houston-area facility in a Sept. 17 Workforce Adjustment and Retraining Notification Act filing. Sign up to get our free newsletters delivered straight to your inbox Santa Clara, Calif.-based Abbott is moving the jobs to Temecula, near San Diego, after picking up the Webster facility last year via its $310 million acquisition of Idev Technologies and its peripheral device portfolio, the Houston Business Journal reported . Abbott Labs is restructuring its vascular, nutrition and diagnostics units, expecting to an record $80 million charge this year for severance and other 1-time expenses. Abbott Vascular has been dealing with a decline in sales of its line of drug-eluting stents in part due to market-share losses, while recording an improvement in the Supera line of stents used in peripheral blood vessels it acquired from Idev. Similar entries
IDev Technologies Frequently Asked Questions (FAQ)
When was IDev Technologies founded?
IDev Technologies was founded in 2006.
Where is IDev Technologies's headquarters?
IDev Technologies's headquarters is located at 253 Medical Center Blvd, Webster.
What is IDev Technologies's latest funding round?
IDev Technologies's latest funding round is Acquired.
How much did IDev Technologies raise?
IDev Technologies raised a total of $107.87M.
Who are the investors of IDev Technologies?
Investors of IDev Technologies include Abbott, RiverVest Venture Partners, Bay City Capital, Heron Capital, Piper Sandler and 4 more.
Who are IDev Technologies's competitors?
Competitors of IDev Technologies include Cardiovascular Systems, Itamar Medical, Svelte Medical Systems, Tryton Medical, NeoGraft Technologies and 12 more.
Compare IDev Technologies to Competitors
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.
Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.
PeriTec is a Cleveland, Ohio based company that aims to develop vascular and cardiovascular surgical products. The company's technology involves the incorporation of a biological tissue, peritoneum, into implantable peripheral vascular stents and vascular patches.
Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.
Stent systems develops angioplasty catheters and guidewires, and related interventional products
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.